---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-341187"
form_type: "8-K"
ticker: "VERU"
cik: "0000863894"
company_name: "VERU INC."
filed_at: "2026-08-10T11:00:07+00:00"
generated_at: "2026-08-10T11:06:21.495640+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Veru reports Q3 FY2026 net loss $7.0M; PLATEAU trial fully enrolled with 239 patients

## Summary
- Q3 net loss $7.0M ($0.30/share) vs $7.3M ($0.50/share) prior year; operating loss $7.7M.
- Phase 2b PLATEAU fully enrolled with 239 patients (target 200); interim analysis Q1 2027, final topline Q4 2027.
- USPTO notice of allowance for enobosarm+semaglutide patent; protection until at least Oct 2044.
- Clinical supply agreement with Novo Nordisk for PLATEAU trial announced June 2026.
- Cash $23.9M at June 30, 2026 vs $15.8M at Sept 30, 2025.

## SEC filing metadata
- accession: 0001193125-26-341187
- form_type: 8-K
- ticker: VERU
- cik: 0000863894
- company_name: VERU INC.
- filed_at: 2026-08-10T11:00:07+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/863894/000119312526341187/0001193125-26-341187-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/863894/000119312526341187/d123580d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-341187
- JSON: https://secwatch.observer/filing/0001193125-26-341187.json
- Plain text: https://secwatch.observer/filing/0001193125-26-341187.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.